Clinical Trial Update: mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares mFOLFOX6 plus bevacizumab with a PD-1 monoclonal antibody versus standard mFOLFOX6 in locally advanced pMMR/MSS colorectal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MFOLFOX6
• PD-1 monoclonal antibody

Snippet

Sponsor: Jun Huang | Conditions: Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum | Phase 3 | Status: RECRUITING